2023 annual financial data
Spero Therapeutics 2023 Operating margin
Spero Therapeutics 2023 operating margin with verified reported values.
Direct answer
Operating margin was 20.7%.
Operating income was 21,481,000 USD and net income was 22,806,000 USD.
Operating cash flow was -32,995,000 USD.
Get free Spero Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 103,781,000 USD
- Operating income
- 21,481,000 USD
- Net income
- 22,806,000 USD
- Operating cash flow
- -32,995,000 USD